UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) ~~January 9~~February 10, 2026

EDWARDS LIFESCIENCES CORPORATION

(Exact name of registrant as specified in its charter)

Delaware

1-15525

36-4316614

(State or other jurisdiction
of incorporation)

(Commission
file number)

(IRS Employer
Identification No.)

One Edwards Way

Irvine, California 92614

(Address of principal executive offices and zip code)

(949) 250-2500

(Registrant's telephone number, including area code)


N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $1.00 per share	EW	New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).

Emerging growth company ☐

~~Item~~If ~~7.01.~~an ~~Other~~emerging ~~Events~~growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

OnItem January 9, 2026 Edwards Lifesciences Corporation (the “Company”) issued a press release announcing that the United States District Court for the District of Columbia has granted the motion from the U2.S02. Results ~~Federal Trade Commission for an injunction blocking the Company’s proposed acquisition~~ of ~~JenaValve~~Operations ~~Technology,~~and ~~Inc~~Financial ~~(“JenaValve”)~~Condition. ~~As a result, the Company will not acquire JenaValve.~~

AOn ~~copy of the press release is attached as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K~~February 10, ~~the information in this Item 7.01~~2026, ~~including~~Edwards ~~Exhibit~~Lifesciences ~~99.1~~Corporation, ~~shall~~a ~~not~~Delaware becorporation ~~deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended~~ (~~the~~ “~~Exchange Act~~Edwards”), orissued ~~otherwise~~a ~~subject~~press torelease ~~the~~setting ~~liabilities~~forth ofEdwards’ ~~that~~financial ~~section,~~results ~~and~~for ~~shall~~the ~~not~~fourth bequarter ~~incorporated~~of by2025. ~~reference~~A ~~into~~copy ~~any~~of ~~registration statement or other document filed under~~ the ~~Securities~~press ~~Act~~release ofis ~~1933,~~furnished as ~~amended~~Exhibit 99.1, orand ~~the~~is ~~Exchange~~incorporated ~~Act,~~herein ~~except as shall be expressly set forth~~ by ~~specific~~ reference ~~in such filing~~.

The information furnished under this Item 2.02, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended.

Item 9.01. Financial Statements and Exhibits.

~~(d)~~	(d)	Exhibits
~~99.1~~	99.1	Press ~~Release~~release, ofdated ~~Edwards~~February ~~Lifesciences~~10, ~~Corporation~~2026, ~~dated~~reporting asEdwards’ offinancial ~~January~~results 9,for ~~2026~~the fourth quarter of 2025.
~~104~~	104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EDWARDS LIFESCIENCES CORPORATION

Date: February 10, 2026

By:

/s/ Mark D. Peterson

EDWARDS LIFESCIENCES CORPORATION

Mark D. Peterson

By:

/s/ Scott B. Ullem

Date: January 9, 2026

Corporate Vice President, General Counsel

Scott B. Ullem

Chief Financial Officer

Exhibit Index


Exhibit Number						Description
99.1						Press release, dated February 1 0 , 20 2 6 , reporting Edwards’ financial results for the fourth quarter of 2025.
104						Cover Page Interactive Data File (embedded within the Inline XBRL document).

Filing Compare · Edwards Lifesciences Corp